Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study

Abstract

CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) ± rituximab [(±R)CHOP] is the current standard of care for aggressive non-Hodgkin lymphoma (NHL). Anemia resulting from chemotherapy can be treated with erythropoiesis-stimulating agents (ESAs). As part of the observational IMPACT NHL study, data were collected on ESA use and anemia-related outcomes in 1829 adults receiving (±R)CHOP-14 or (±R)CHOP-21. Overall, 33% of patients were anemic during chemotherapy. Older age, lower baseline hemoglobin (Hb), worse performance status, more advanced disease stage, and use of CHOP-14 were significant predictors of transfusion and anemia in logistic regression models. ESAs were received by 404 patients, usually in response to low or declining Hb levels. Most patients (65%) had Hb 9–11 g/dL at ESA initiation, and 89% (Kaplan–Meier percentage) achieved Hb 10–12 g/dL. In conclusion, two-thirds of anemic patients with NHL receiving (±R)CHOP initiated ESA treatment at Hb 9–11 g/dL, and most achieved target Hb levels (10–12 g/dL).

Keywords:

• CHOP chemotherapy
• non-Hodgkin lymphoma
• observational study
• erythropoiesis-stimulating agents
• anemia

Acknowledgements

Medical writing assistance was provided by Dr Daniel Booth (Bioscript Stirling Ltd., London, UK) and funded by Amgen (Europe) GmbH.

Potential conflict of interest: Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.